Roche discontinues Genmab cancer drug
08 December 2009
Malini Guha
Please Login to read the full article.
08 December 2009
Malini Guha
Malini.guha@informa.com
Roche has discontinued development of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor, RG1507, which was the most advanced product it was developing in collaboration with Genmab for various cancers.
RG1507 was in Phase II development for multiple indications, including non-small-cell...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Aeterna's test for adult growth hormone deficiency reaches goal in PhIII study
- New research sheds more light on secondary tumours with Roche/Plexxikon's Zelboraf
- Novelos Therapeutics to raise $5.9M as it advances cancer-targeted compounds
- Genmab winds down zalutumumab in absence of partner
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
